Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases

Lipids in Health and Disease

Volumn 7, Issue , 2008, Pages

  Jiang, Jingting ^a   Zhang, Xiaoying ^a   Wu, Changping ^a   Qin, Xihu ^a   Luo, Guanghua ^a   Deng, Haifeng ^a   Lu, Minyang ^a   Xu, Bin ^a   Li, Min ^a   Ji, Mei ^a   Xu, Ning ^b  

^a SOOCHOW UNIVERSITY   (China)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN M; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; APOLIPOPROTEIN; APOM PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING; BLOOD; CASE CONTROL STUDY; CHRONIC DISEASE; HEPATITIS; LIVER DISEASE; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HEPATITIS; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; MALE; MIDDLE AGED;

EID: 49349104534     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-7-25     Document Type: Article

References (33)

1. Hepatocellular carcinoma: the high-risk patient. NN Nissen P Martin, J Clin Gastroenterol 2002 35 5 Suppl 2 S79 85 10.1097/00004836-200211002-00003 12394210
2. Mortality of primary liver cancer in China from 1990 through 1992(Chinese article). Zhang SW Li LD Lu FZ Mu R Sun XD HuangP XM Sun J Zhou YC D XD, Chinese Journal of Oncology 1999 21 4 245 249 11776805
3. Hepatitis B and primary liver cancer. TJ Harrison JY Chen AJ Zuckerman, Cancer Treat Rev 1986 13 1 1 16 10.1016/0305-7372(86)90011-3 3013403
4. Mammalian hepatitis B viruses and primary liver cancer. MA Buendia, Semin Cancer Biol 1992 3 5 309 320 1335794
5. Molecular mechanisms of hepatitis B virus-associated liver cancer. C Rabe B Cheng WH Caselmann, Dig Dis 2001 19 4 279 287 10.1159/000050694 11935087
6. Influence of liver cancer on lipid and lipoprotein metabolism. J Jiang P Nilsson-Ehle N Xu, Lipids Health Dis 2006 5 4 16515689 10.1186/1476-511X-5-4
7. Serum apoprotein A-I and A-II levels in liver diseases and cholestasis. S Fujii S Koga T Shono K Yamamoto H Ibayashi, Clin Chim Acta 1981 115 3 321 331 10.1016/0009-8981(81)90245-X 6271423
8. Clinical significance of abnormal lipoprotein patterns in liver diseases. K Ooi K Shiraki Y Sakurai Y Morishita T Nobori, Int J Mol Med 2005 15 4 655 660 15754028
9. Serum apolipoproteins A-I, A-II and B in hepatic metastases. Comparison with other liver diseases: hepatomas and cirrhosis. H Hachem G Favre G Raynal G Blavy P Canal G Soula, J Clin Chem Clin Biochem 1986 24 3 161 166 2872262
10. Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. XY Zhang X Dong L Zheng GH Luo YH Liu U Ekstrom P Nilsson-Ehle Q Ye N Xu, Acta Histochem 2003 105 1 67 72 10.1078/0065-1281-00687 12666989
11. A novel human apolipoprotein (apoM). N Xu B Dahlback, J Biol Chem 1999 274 44 31286 31290 10.1074/jbc.274.44.31286 10531326
12. Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo. N Xu P Nilsson-Ehle M Hurtig B Ahren, Biochem Biophys Res Commun 2004 321 4 916 921 10.1016/j.bbrc.2004.06.180 15358114
13. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. C Cicognani M Malavolti AM Morselli-Labate L Zamboni C Sama L Barbara, Arch Intern Med 1997 157 7 792 796 10.1001/archinte.157.7.792 9125012
14. Lipoprotein (a) behaviour in patients with hepatocellular carcinoma. M Motta I Giugno P Ruello G Pistone I Di Fazio M Malaguarnera, Minerva Med 2001 92 5 301 305 11675573
15. Serum lipids in hepatoma. EA Alsabti, Oncology 1979 36 1 11 14 221872
16. Cell compartmentalization of cholesterol biosynthesis. SK Krisans, Ann N Y Acad Sci 1996 804 142 164 10.1111/j.1749-6632.1996.tb18614.x 8993542
17. Estimation of dolichol and cholesterol synthesis in microsomes and peroxisomes isolated from rat liver. J Grunler JM Olsson G Dallner, FEBS Lett 1995 358 3 230 232 10.1016/0014-5793(94)01431-Y 7843406
18. Effects of liver transplantation and resection on lipid parameters: a longitudinal study. ME Cooper A Akdeniz KJ Hardy, Aust N Z J Surg 1996 66 11 743 746 10.1111/j.1445-2197.1996.tb00734.x 8918381
19. Abnormal lipid and lipoprotein patterns in liver cirrhosis with and without hepatocellular carcinoma. JE Ahaneku GO Taylor IO Olubuyide EO Agbedana, J Pak Med Assoc 1992 42 11 260 263 1336073
20. High-density lipoprotein cholesterol and liver disease. GC Kanel G Radvan RL Peters, Hepatology 1983 3 3 343 348 6840679
21. Treatment of nonresectable hepatocellular carcinoma: review of the literature and meta-analysis. M Malaguarnera G Trovato S Restuccia I Giugno CM Franze G Receputo R Siciliano M Motta BA Trovato, Adv Ther 1994 11 6 303 319 10150270
22. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. HG Kraft HJ Menzel F Hoppichler W Vogel G Utermann, J Clin Invest 1989 83 1 137 142 2521341 10.1172/JCI113849
23. Lipoprotein(a) in cirrhosis. A new index of liver functions? M Malaguarnera I Giugno BA Trovato MP Panebianco N Restuccia P Ruello, Curr Med Res Opin 1996 13 8 479 485 9010614
24. Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man. F Krempler GM Kostner A Roscher F Haslauer K Bolzano F Sandhofer, J Clin Invest 1983 71 5 1431 1441 6304146 10.1172/JCI110896
25. Radioimmunoassay of human plasma Lp(a) lipoprotein. JJ Albers JL Adolphson WR Hazzard, J Lipid Res 1977 18 3 331 338 405443
26. Hypercoagulable states in patients with hepatocellular carcinoma. DN Samonakis IE Koutroubakis A Sfiridaki N Malliaraki P Antoniou J Romanos EA Kouroumalis, Dig Dis Sci 2004 49 5 854 858 10.1023/B:DDAS.0000030099.13397.28 15259509
27. Antibodies against ox-LDL serum levels in patients with hepatocellular carcinoma. M Motta G Pistone AM Franzone MA Romeo S Di Mauro I Giugno P Ruello M Malaguarnera, Panminerva Med 2003 45 1 69 73 12682623
28. Low lipoprotein (a) levels during acute viral hepatitis. HC Geiss MM Ritter WO Richter P Schwandt R Zachoval, Hepatology 1996 24 6 1334 1337 10.1002/hep.510240602 8938156
29. Lipoprotein (a) serum levels in patients with hepatocarcinoma. S Basili P Andreozzi M Vieri M Maurelli D Cara C Cordova C Alessandri, Clin Chim Acta 1997 262 1-2 53 60 10.1016/S0009-8981(97)06533-9 9204209
30. The behaviour of lipoprotein(a) in patients with various diseases. JW Van Wersch, Scand J Clin Lab Invest 1994 54 7 559 562 10.3109/00365519409088568 7863233
31. New insights into the regulation of HDL metabolism and reverse cholesterol transport. GF Lewis DJ Rader, Circ Res 2005 96 12 1221 1232 10.1161/01.RES.0000170946.56981.5c 15976321
32. The lipid composition of serum in patients with liver disease. GB Phillips, J Clin Invest 1960 39 1639 1650 13735297 10.1172/JCI104187
33. Increased proportion of proapolipoprotein A-I in HDL from patients with liver cirrhosis and hepatitis. T Matsuura S Koga H Ibayashi, Gastroenterol Jpn 1988 23 4 394 400 2846400